Search

Mariko Nagashima

from San Mateo, CA
Age ~69

Mariko Nagashima Phones & Addresses

  • 128 El Camino Real, San Mateo, CA 94401
  • 8 Court Ln, San Mateo, CA 94404
  • Foster City, CA
  • Sacramento, CA
  • Los Angeles, CA
  • San Bruno, CA
  • Hillsborough, CA
  • Folsom, CA

Industries

Writing and Editing

Resumes

Resumes

Mariko Nagashima Photo 1

Mariko Nagashima

View page
Location:
San Francisco Bay Area
Industry:
Writing and Editing

Publications

Us Patents

Thrombomodulin Analogs For Pharmaceutical Use

View page
US Patent:
6632791, Oct 14, 2003
Filed:
Jun 12, 2001
Appl. No.:
09/880484
Inventors:
David Light - San Mateo CA
Michael John Morser - San Francisco CA
Mariko Nagashima - Belmont CA
Assignee:
Schering Aktiengesellschaft - Berlin
International Classification:
A61K 3800
US Classification:
514 8, 530350
Abstract:
The present invention relates to the design, production and use of analogs of thrombomodulin (TM) that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to promote activation of thrombin-activatable fibrinolysis inhibitor (TAFI). These analogs are useful in, for example, antithrombotic therapy.

Thrombomodulin Analogs For Pharmaceutical Use

View page
US Patent:
6790828, Sep 14, 2004
Filed:
May 14, 2003
Appl. No.:
10/438648
Inventors:
David Light - San Mateo CA
Michael John Morser - San Francisco CA
Mariko Nagashima - Belmont CA
Assignee:
Schering Aktiengesellschaft - Berlin
International Classification:
A61K 3816
US Classification:
514 8
Abstract:
The present invention relates to the design, production and use of analogs of thrombomodulin (TM) that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to promote activation of thrombin-activatable fibrinolysis inhibitor (TAFI). These analogs are useful in, for example, antithrombotic therapy.

Tafi Inhibitors And Their Use To Treat Pulmonary Fibrosis

View page
US Patent:
2006010, May 18, 2006
Filed:
Oct 3, 2005
Appl. No.:
11/242524
Inventors:
Hajime Fujimoto - Tsu City,
Esteban Gabazza - Tsu City,
Michael Morser - San Francisco CA,
Mariko Nagashima - Belmont CA,
Osamu Taguchi - Tsu City,
Assignee:
Schering Aktiengesellschaft - Berlin
Mie University Graduate School of Medicine - Tsu City
International Classification:
A61K 31/69
A61K 31/445
A61K 31/41
A61K 31/66
A61K 31/195
US Classification:
514064000, 514114000, 514381000, 514315000, 514562000
Abstract:
The invention relates to TAFI inhibitors and their use to treat pulmonary fibrosis.

Use Of Tafi Inhibitors For Enhanced Myocardial Reperfusion And Facilitated Pci

View page
US Patent:
2006023, Oct 19, 2006
Filed:
Apr 11, 2006
Appl. No.:
11/402499
Inventors:
Brad Buckman - Oakland CA,
William Dole - Ipswich MA,
Kohichi Kawai - Mihama-ku,
Michael Morser - San Francisco CA,
Mariko Nagashima - Belmont CA,
Ronald Vergona - Sonoma CA,
Yi-Xin Wang - Lafayette CA,
Assignee:
Schering Aktiengesellschaft - Berlin
International Classification:
A61K 31/445
A61K 31/195
A61K 31/66
US Classification:
514114000, 514315000, 514562000
Abstract:
This invention relates to TAFI inhibitors and their use to enhance myocardial reperfusion and facilitate percutaneous coronary intervention (PCI) in the treatment of acute ST elevation myocardial infarction (STEMI).

Antibodies To Advanced Glycosylation End-Product Receptor Polypeptides And Uses Therefor

View page
US Patent:
5864018, Jan 26, 1999
Filed:
Apr 16, 1996
Appl. No.:
8/633148
Inventors:
Michael John Morser - San Francisco CA
Mariko Nagashima - Belmont CA
Assignee:
Schering Aktiengesellschaft - Berlin
International Classification:
C07K 1600
US Classification:
5303871
Abstract:
It is a general object of the present invention to provide compositions that specifically interact with advanced glycosylation end products (AGEs) or their receptors. Such compositions may be used in a variety of applications including therapeutic applications, e. g. , as blocking agents to inhibit or otherwise reduce the AGE/RAGE interaction, screening applications, e. g. , as models of the AGE/RAGE interaction, and diagnostic applications, e. g. , to identify abnormal levels of AGE or RAGE in a given system.

Method Of Detecting Thrombotic Disease Risk Associated With Plasma Carboxypeptidase B Polymorphisms

View page
US Patent:
5985562, Nov 16, 1999
Filed:
Jun 3, 1997
Appl. No.:
8/869057
Inventors:
Michael John Morser - San Francisco CA
Mariko Nagashima - Belmont CA
Assignee:
Schering Aktiengesellschaft - Berlin
International Classification:
C12Q 168
C12P 1934
G01N 3353
US Classification:
435 6
Abstract:
Polymorphisms within a plasma carboxypeptidase designated plasma carboxypeptidase B (PCPB) have been identified. The relative distribution of these polymorphs in a patient's blood can be used to assess an individual's risk toward thrombotic disease.
Mariko Nagashima from San Mateo, CA, age ~69 Get Report